Troponin‐I levels as a potential prognostic biomarker of sacubitril/valsartan treatment response in heart failure with reduced ejection fraction: Who will benefit most?

• Published in: Clinical cardiology (Mahwah, N.J.) Vol. 41; no. 12; pp. 1548 - 1554
• Main Authors: Nakou, Eleni S., Marketou, Maria E., Chlouverakis, Gregory I., Patrianakos, Alexandros P., Vardas, Panos E., Parthenakis, Fragiskos I.
• Format: Journal Article
• Language: English
• Published: New York Wiley Periodicals, Inc 01.12.2018; John Wiley & Sons, Inc
• Subjects: Aged; Aminobutyrates - therapeutic use; Biomarkers - blood; cardiopulmonary exercise; Clinical Investigations; Drug Combinations; Echocardiography; Ejection fraction; Exercise Test; Female; Follow-Up Studies; Heart failure; Heart Failure - blood; Heart Failure - drug therapy; Heart Failure - physiopathology; Heart Ventricles - diagnostic imaging; Heart Ventricles - physiopathology; Humans; Male; predictive biomarkers; Prognosis; Prospective Studies; sacubitril/valsartan; Stroke Volume - physiology; Tetrazoles - therapeutic use; Troponin I - blood; Ventricular Function, Left - physiology; heart failure; predictive biomarkers; cardiopulmonary exercise; sacubitril/valsartan

Background Despite robust data on the benefits of sacubitril/valsartan (LCZ696) in patients with chronic heart failure with reduced ejection fraction (HFrEF), there is no evidence yet on prespecified predictive markers of its efficacy. Hypothesis The objective of this study was to identify potential...